Dermatology Times has published its quarterly regulatory and pipeline review covering the third quarter of 2026, cataloging the FDA approvals and clinical readouts that shaped dermatologic practice over the period.

The review series tracks approvals, label updates, and late-stage trial results across the specialty's major therapeutic areas — inflammatory disease, skin cancer, and medical and aesthetic dermatology — and consolidates them for clinicians who need to track a rapidly expanding pipeline.

The full article is available through Dermatology Times' regular FDA and pipeline coverage.

The quarterly format is designed to give practicing dermatologists a single reference point for regulatory movement that affects drug selection, payer conversations, and patient counseling.

Editor's note: Derm Field accessed this item via a syndicated headline feed that did not carry the full article text, including the specific approvals, trial names, endpoints, and effect sizes discussed in the original review. We are not reproducing or summarizing those specifics here because the underlying data did not accompany the syndicated headline. Readers requiring the complete Q3 2026 approval and readout details — including any PASI, EASI, or other endpoint data cited — should consult the original Dermatology Times review directly.

The Q4 2026 installment of the series will presumably follow at the close of the fourth quarter, continuing the outlet's cycle of tracking FDA decisions and pipeline milestones relevant to dermatologic care.